NasdaqGS:OVID

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. More Details


Snowflake Analysis

Flawless balance sheet with high growth potential.

Share Price & News

How has Ovid Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: OVID is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: OVID's weekly volatility (9%) has been stable over the past year.


Market Performance


7 Day Return

-51.0%

OVID

3.9%

US Biotechs

0.7%

US Market


1 Year Return

-27.0%

OVID

24.7%

US Biotechs

22.2%

US Market

Return vs Industry: OVID underperformed the US Biotechs industry which returned 26.3% over the past year.

Return vs Market: OVID underperformed the US Market which returned 22.7% over the past year.


Shareholder returns

OVIDIndustryMarket
7 Day-51.0%3.9%0.7%
30 Day-40.6%14.0%11.8%
90 Day-46.1%14.9%8.6%
1 Year-27.0%-27.0%26.8%24.7%25.0%22.2%
3 Year-74.3%-74.3%27.7%21.1%49.4%39.5%
5 Yearn/a17.3%9.2%100.2%78.1%

Long-Term Price Volatility Vs. Market

How volatile is Ovid Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Ovid Therapeutics undervalued compared to its fair value and its price relative to the market?

2.93x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate OVID's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate OVID's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: OVID is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: OVID is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate OVID's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: OVID is good value based on its PB Ratio (2.9x) compared to the US Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Ovid Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

72.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OVID is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: OVID is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: OVID's is expected to become profitable in the next 3 years.

Revenue vs Market: OVID's revenue (80.4% per year) is forecast to grow faster than the US market (10.2% per year).

High Growth Revenue: OVID's revenue (80.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if OVID's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Ovid Therapeutics performed over the past 5 years?

-19.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OVID is currently unprofitable.

Growing Profit Margin: OVID is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: OVID is unprofitable, and losses have increased over the past 5 years at a rate of 19.7% per year.

Accelerating Growth: Unable to compare OVID's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OVID is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.8%).


Return on Equity

High ROE: OVID has a negative Return on Equity (-119.38%), as it is currently unprofitable.


Next Steps

Financial Health

How is Ovid Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: OVID's short term assets ($90.3M) exceed its short term liabilities ($18.0M).

Long Term Liabilities: OVID's short term assets ($90.3M) exceed its long term liabilities ($10.0M).


Debt to Equity History and Analysis

Debt Level: OVID is debt free.

Reducing Debt: OVID has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OVID has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: OVID has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 30.9% each year.


Next Steps

Dividend

What is Ovid Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate OVID's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OVID's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OVID's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OVID's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OVID's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.4yrs

Average management tenure


CEO

Jeremy Levin (67 yo)

5.75yrs

Tenure

US$3,008,980

Compensation

Dr. Jeremy Max Levin, BA Zoology, DPhil, MB BChir, has been the Chief Executive Officer of Ovid Therapeutics Inc. since March 2015 and serves as its Executive Director. From 1996 to 2000, Dr. Levin has exp...


CEO Compensation Analysis

Compensation vs Market: Jeremy's total compensation ($USD3.01M) is above average for companies of similar size in the US market ($USD1.14M).

Compensation vs Earnings: Jeremy's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Jeremy Levin
Chairman & CEO5.75yrsUS$3.01m9.13%
$ 17.0m
Amit Rakhit
President & Chief Medical Officer1.08yrsUS$1.59m0.016%
$ 30.1k
Timothy Daly
Executive VP of Finance1.08yrsUS$897.28k0.015%
$ 28.7k
Matthew During
Founder & Chairman of Scientific Advisory Board1.67yrsUS$1.39m6.79%
$ 12.6m
Lora Pike
Senior Director of Investor Relations & Public Relationsno datano datano data
Thomas Perone
General Counsel1.75yrsno datano data
Suzanne Wakamoto
Senior Vice President of Human Resourcesno datano datano data
Anna Kazanchyan
Senior Vice President of Product Developmentno datano datano data
Dirk Haasner
Senior Vice President of Manufacturing & CMC QA4.75yrsUS$1.18mno data
Claude Nicaise
Head of Strategic Orphan Regulatory Affairsno datano datano data
Jason Tardio
Chief Commercial Officer1.08yrsno datano data
Luke Rosen
Vice President of Patient Engagement & Government Affairsno datano datano data

1.4yrs

Average Tenure

55yo

Average Age

Experienced Management: OVID's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Jeremy Levin
Chairman & CEO5.75yrsUS$3.01m9.13%
$ 17.0m
Matthew During
Founder & Chairman of Scientific Advisory Board1.67yrsUS$1.39m6.79%
$ 12.6m
Douglas Williams
Independent Director4.92yrsUS$85.71k0.0079%
$ 14.7k
Barbara Duncan
Independent Director3.5yrsUS$75.71k0%
$ 0
Bart Friedman
Lead Independent Directorno dataUS$88.21k0%
$ 0
Jacqueline French
Member of Scientific Advisory Board3.92yrsno datano data
Howard Federoff
Member of Scientific Advisory Boardno datano datano data
Karen Bernstein
Independent Director5.25yrsUS$85.71k0.032%
$ 58.7k
Daniel Geschwind
Member of Scientific Advisory Board4.67yrsno datano data
David Eidelberg
Member of the Scientific Advisory Boardno datano datano data
Alexander Kolevzon
Member of Scientific Advisory Board0.75yrno datano data

4.3yrs

Average Tenure

65yo

Average Age

Experienced Board: OVID's board of directors are considered experienced (4.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 32.7%.


Top Shareholders

Company Information

Ovid Therapeutics Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Ovid Therapeutics Inc.
  • Ticker: OVID
  • Exchange: NasdaqGS
  • Founded: 2014
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$186.182m
  • Shares outstanding: 63.44m
  • Website: https://www.ovidrx.com

Number of Employees


Location

  • Ovid Therapeutics Inc.
  • 1460 Broadway
  • Suite 15044
  • New York
  • New York
  • 10036
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OVIDNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMay 2017
1OTDB (Deutsche Boerse AG)YesCommon StockDEEURMay 2017

Biography

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candida...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/12/03 00:18
End of Day Share Price2020/12/02 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.